Business Standard -- The pharmaceutical industry’s buying spree will continue and investors may see more big deals as drugmakers seek ways to stave off business pressures, a GlaxoSmithKline executive said on Tuesday.
Business Standard -- The pharmaceutical industry’s buying spree will continue and investors may see more big deals as drugmakers seek ways to stave off business pressures, a GlaxoSmithKline executive said on Tuesday.
